Médecine

Paramédical

Autres domaines


S'abonner

Anticoagulant activity and pleiotropic effects of heparin - 13/05/20

Doi : 10.1016/j.jdmv.2020.03.002 
C. Bal dit Sollier a, b, J.-G. Dillinger a, b, L. Drouet a, b,
a CREATIF (Centre de Référence et d’Éducation aux AntiThrombotiques d’Île de France), Lariboisière Hospital, 2, rue Ambroise Paré, 75475 Paris cedex 10, France 
b Department of Cardiology, Lariboisière Hospital, 2, rue Ambroise Paré, 75475 Paris cedex 10, France 

Corresponding author at: Department of Cardiology, Lariboisière Hospital, 2, rue Ambroise Paré, 75475 Paris cedex 10, France.Department of Cardiology, Lariboisière Hospital2, rue Ambroise ParéParis cedex 1075475France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

The recognized therapeutic effect of heparins is an anticoagulant activity (anti-Xa and anti-IIa) acting in an indirect manner (cofactor of antithrombin) but which is carried by only 20% at best of the glycan chains composing any commercial preparation of heparin, whether unfractionated or low molecular weight. However, the effects of glycan chains that participate in the therapeutic but also potentially adverse effects of heparin preparations must also be considered. These specific effects of glycans are potentially different for each commercial preparation of heparins and, in particular, low molecular weight heparins (LMWH) compared with unfractionated heparin (UFH) and LMWH between them. The glycanic nature of heparin is responsible for its very particular pharmacology: exchange with the glycocalyx of cells in particular endothelial. Exchanges which depend on the length and structure of the glycan chains therefore different between UFH and LMWH between the different heparin preparations between them but also according to the state of glycocalyx differently altered according to the underlying diseases and their degree of evolution. If the anticoagulant effects of heparins can potentially be replaced with those of new oral anticoagulants, the glycan effects of heparins cannot be replaced by synthetic non-glycan molecules. This replacement will undoubtedly limit certain risks such as heparin-induced thrombocytopenia (HIT) but other beneficial effects participating to the overall efficacy of heparin (whose relative importance remains to be ascertained), will also disappear: effects on surfaces, anti-inflammatory effects, antineoplastic and anti-metastatic effects, ancillary anticoagulant effects (not dependent on antithrombin), effect on endothelial dysfunction. This review will be focused on all of these related/pleiotropic effects of heparins that are in fact the effects of the glycan nature of heparin. Among the antithrombotic effects not dependent on antithrombin one has been more recently highlighted: the passivation/neutralization of the positively charged fibrils of Netosis, by the negatively charged glycan chains of heparin. This also has clinical implications: in the era of generics and biosimilars where biosimilar heparins begin to appear, it is important to know that accordingly to FDA and EMEA rules: their biosimilarity is judged only on the “classical” anticoagulation effect cofactor of antithrombin (anti-IIa/anti-Xa) but that all glycan effects that are potentially beneficial or potentially deleterious are not taken into consideration in their assessment.

Le texte complet de cet article est disponible en PDF.

Keywords : Heparin, Non-fractionated heparin, Low molecular weight heparin, Glycanes, Glycocalyx, Netosis


Plan


© 2020  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 45 - N° 3

P. 147-157 - mai 2020 Retour au numéro
Article précédent Article précédent
  • Update of the SFMV (French society of vascular medicine) guidelines on the conditions and safety measures necessary for thermal ablation of the saphenous veins and proposals for unresolved issues
  • S. Gracia, G. Miserey, J. Risse, F. Abbadie, J.F. Auvert, B. Chauzat, P. Combes, D. Creton, O. Creton, L. Da Mata, A. Diard, P. Giordana, M. Josnin, O. Keïta-Perse, A. Lasheras, P. Ouvry, O. Pichot, S. Skopinski, G. Mahé
| Article suivant Article suivant
  • Traumatic renal artery pseudoaneurysm on a pelvic kidney
  • Ahmed Ibrahimi, Othman Zahdi, Hamza Dergamoun, Idriss Ziani, Hachem El Sayegh, Lounis Benslimane, Brahim Lekehal, Yassine Nouini

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.